A5010339451- Immune cells in cancer
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Pancreatic and Hepatic Oncology Research
- Nanoplatforms for cancer theranostics
- Epigenetics and DNA Methylation
- Neuroinflammation and Neurodegeneration Mechanisms
- Immune Response and Inflammation
- Chemokine receptors and signaling
- Cancer, Stress, Anesthesia, and Immune Response
- Phagocytosis and Immune Regulation
- Galectins and Cancer Biology
- Macrophage Migration Inhibitory Factor
- T-cell and B-cell Immunology
- Anesthesia and Neurotoxicity Research
- Neuropeptides and Animal Physiology
- Cancer Cells and Metastasis
Herlev Hospital
2022-2025
Copenhagen University Hospital
2021-2024
University of Copenhagen
2022
Arginase-1 (Arg1) expressing tumor-associated macrophages (TAMs) may create an immune-suppressive tumor microenvironment (TME), which is a significant challenge for cancer immunotherapy. We previously reported the existence of Arg1-specific memory T cells among peripheral blood mononuclear (PBMCs) and described that Arg-1-based immune modulatory vaccines (IMVs) control growth alter M1/M2 macrophage ratio in murine models cancer. In present study, we investigated how can directly target TAMs...
The tumor microenvironment (TME) of pancreatic cancer is highly immunosuppressive. We recently developed a transforming growth factor (TGF)β-based immune modulatory vaccine that controlled in murine model by targeting immunosuppression and desmoplasia the TME. found treatment with TGFβ not only reduced percentage M2-like tumor-associated macrophages (TAMs) cancer-associated fibroblasts (CAFs) but polarized CAFs away from myofibroblast-like phenotype. However, whether properties on TAM CAF...
Expression of the L-arginine catabolizing enzyme arginase 1 (ARG1) is a central immunosuppressive mechanism mediated by tumor-educated myeloid cells. Increased activity ARG1 promotes formation an microenvironment and leads to more aggressive phenotype in many cancers. Intrinsic T-cell immunity against ARG1-derived epitopes peripheral blood cancer patients healthy subjects has previously been demonstrated. To evaluate antitumor efficacy peptide vaccines as monotherapy combinational therapy...
Pancreatic ductal adenocarcinoma (PDAC) is associated with very poor survival, making it the third and fourth leading cause of all cancer-related deaths in USA European Union, respectively. The tumor microenvironment (TME) PDAC highly immunosuppressive desmoplastic, which could explain limited therapeutic effect immunotherapy PDAC. One key molecules that contributes to immunosuppression fibrosis transforming growth factor-β (TGFβ). aim this study was target fibrotic TME using a novel immune...
CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. was shown to play key role in suppressing anti-cancer immune responses different cancer types. Recently, we showed CCL22-specific generated from patients could kill CCL22-expressing tumor and directly influence levels of vitro. The present study aimed provide rationale for developing CCL22-targeting immunotherapy. Vaccination with CCL22-derived peptides induced T-cell both...
Galectin-3 (Gal3) can be expressed by many cells in the tumor microenvironment (TME), including cancer cells, cancer-associated fibroblasts, tumor-associated macrophages, and regulatory T (Tregs). In addition to immunosuppression, Gal3 expression has been connected malignant cell transformation, progression, metastasis. present study, we found spontaneous T-cell responses against Gal3-derived peptides PBMCs from both healthy donors patients. We isolated expanded these Gal3-specific vitro...
High expression of the metabolic enzyme arginase-2 (ARG2) by cancer cells, regulatory immune or cells tumor stroma can reduce availability arginine (L-Arg) in microenvironment (TME). Depletion L-Arg has detrimental consequences for T and leads to T-cell dysfunction suppression anticancer responses. Previous work from our group demonstrated presence proinflammatory ARG2-specific CD4 that inhibited growth murine models on activation with ARG2-derived peptides. In this study, we investigated...
Abstract Although interleukin (IL)-6 is considered immunosuppressive and tumor-promoting, emerging evidence suggests that it may support antitumor immunity. While combining immune checkpoint inhibitors (ICIs) radiotherapy in patients with pancreatic cancer (PC) has yielded promising clinical results, the addition of an anti-IL-6 receptor (IL-6R) antibody failed to elicit benefits. Notably, a robust TGFβ-specific response at baseline PC treated solely ICIs correlated improved survival. Recent...
<title>Abstract</title> β-adrenergic signaling has been suggested to promote tumor growth, and β-blockers are being evaluated for repurposing cancer treatment. Here, we identify a novel axis involved in metastasis formation. We show that the β-blocker propranolol strong anti-metastatic activity multiple murine models, with this effect completely dependent on CD4+ T cells. Notably, of is unaffected by depletion NK or CD8+ Propranolol induces Th1-polarized cytotoxic cell response, which...
<div>Abstract<p>Expression of the L-arginine catabolizing enzyme arginase 1 (ARG1) is a central immunosuppressive mechanism mediated by tumor-educated myeloid cells. Increased activity ARG1 promotes formation an microenvironment and leads to more aggressive phenotype in many cancers. Intrinsic T-cell immunity against ARG1-derived epitopes peripheral blood cancer patients healthy subjects has previously been demonstrated. To evaluate antitumor efficacy peptide vaccines as...
<p>Collected supplementary data file with figures and figure legends.</p>
<div>Abstract<p>Expression of the L-arginine catabolizing enzyme arginase 1 (ARG1) is a central immunosuppressive mechanism mediated by tumor-educated myeloid cells. Increased activity ARG1 promotes formation an microenvironment and leads to more aggressive phenotype in many cancers. Intrinsic T-cell immunity against ARG1-derived epitopes peripheral blood cancer patients healthy subjects has previously been demonstrated. To evaluate antitumor efficacy peptide vaccines as...
<p>Collected supplementary data file with figures and figure legends.</p>